ClinicalTrials.gg
RecruitingNCT05197920DREAMUpdated Nov 19, 2026

Diabetes RElated to Acute Pancreatitis and Its Mechanisms

An observational study in Acute Pancreatitis, sponsored by Milton S. Hershey Medical Center. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Milton S. Hershey Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Nov 19, 2026Sponsor changedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
12th of 41
800 · median 433
Started
2022
with 10 others
Observational
42 of 139
15 open now
Primary completion
2030-01
later than 42 of 48 live
Registered
99th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 12th largest by planned enrollment of the 41 observational ones that give a count, is one of 11 that started in 2022, is one of 42 observational ones, reaches primary completion later than 42 of the 48 other live ones, and was the 99th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).

Read the detailed description

The DREAM investigators will conduct dynamic metabolic testing that includes oral glucose tolerance testing (OGTT), mixed meal tolerance testing (MMTT), and frequently sampled intravenous glucose tolerance testing (FSIGTT). These tests will increase the sensitivity for DM diagnosis (with OGTT) and to assess beta cell function and other pancreatic and enteroendocrine hormones involved in maintaining glucose homeostasis (OGTT, MMTT and FSIGTT). The DREAM research hypotheses are as follows.

  1. There is a cumulative increase in the risk of any type of DM after an episode of AP, and the development of DM after AP is influenced by several patient and disease-related factors (e.g. age, etiology, disease severity).
  2. After AP is clinically resolved, there is ongoing subclinical beta cell damage that predisposes to delayed-onset of DM.
  3. AP triggers an altered immune state in a subset of individuals that predisposes to islet autoimmunity and DM.
03

Conditions studied

  • Acute Pancreatitis

Keywords

  • Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized for acute pancreatitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date
  • Participant fully understands and is able to participate in all aspects of the study, including providing , completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP
  • Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \<48 hours.
  • Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study
  • Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and
  • Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)
  • Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure
  • Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures
  • Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate (eGFR) \< 30 or on dialysis prior to AP, and cirrhosis (based on imaging or ), or any other medical condition that in the opinion of the site-PI carries a of \<12 months.
  • Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety
  • Incarceration
  • Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP)

    time to onset of DM during the 36-month longitudinal follow-up period

    Time frame: any time during the 36-month longitudinal follow-up period

Secondary outcomes

  1. PROMIS Global Health

    Patient Reported Outcomes Measurement Information System (PROMIS) Global Health, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  2. PROMIS Pain Intensity

    Patient Reported Outcomes Measurement Information System (PROMIS) Pain Intensity, measured on an 11-point scale from 0 (no pain ) to 10 (worst pain imaginable)

    Time frame: months 3, 12, 24, and 36

  3. PROMIS-29 Physical Function

    PROMIS-29 Physical Function, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  4. PROMIS-29 Anxiety

    PROMIS-29 Anxiety, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  5. PROMIS-29 Depression

    PROMIS-29 Depression, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  6. PROMIS-29 Fatigue

    PROMIS-29 Fatigue, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  7. PROMIS-29 Sleep Disturbance

    PROMIS-29 Sleep Disturbance, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  8. PROMIS-29 Ability to Participate in Social Roles and Activities

    PROMIS-29 Ability to Participate in Social Roles and Activities, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  9. PROMIS-29 Pain Interference

    PROMIS-29 Pain Interference, converted to a t-score with a mean of 50 and a standard deviation of 10

    Time frame: months 3, 12, 24, and 36

  10. OGTT Insulin Secretion

    Oral Glucose Tolerance Testing (OGTT) Insulin Secretion, as measured by the insulin area under the curve relative to the glucose area under the curve

    Time frame: months 3, 12, 24, and 36

  11. OGTT Insulin Sensitivity Index

    Oral Glucose Tolerance Testing (OGTT) Insulin Sensitivity Index, as measured by the glucose disposal rate divided by the average plasma insulin concentration

    Time frame: months 3, 12, 24, and 36

  12. MMTT Incretin Hormones: GIP and GLP-1

    Mixed Meal Tolerance Testing (MMTT) Incretin Hormones: Glucose-dependent Insulinotropic Polypeptide (GIP, pmol/L) and Glucagon-like Peptide-1 (GLP-1, pmol/L)

    Time frame: months 3, 12, 24, and 36

  13. MMTT Glucagon

    Mixed Meal Tolerance Testing (MMTT) Glucagon (pg/mL)

    Time frame: months 3, 12, 24, and 36

  14. MMTT Pancreatic Polypeptide (PP)

    Mixed Meal Tolerance Testing (MMTT) Pancreatic Polypeptide (PP, pg/mL)

    Time frame: months 3, 12, 24, and 36

  15. FSIGTT Acute Insulin Response to Glucose (AIRglu)

    Frequently Sampled Intravenous Glucose Tolerance Testing (FSIGTT) Acute Insulin Response to Glucose (AIRglu)

    Time frame: months 3 and 12

  16. FSIGTT Acute C-peptide Response to Glucose (ACRglu)

    Frequently Sampled Intravenous Glucose Tolerance Testing (FSIGTT) Acute C-peptide Response to Glucose (ACRglu)

    Time frame: months 3 and 12

  17. FSIGTT Total Body Insulin Sensitivity Index (SI)

    Frequently Sampled Intravenous Glucose Tolerance Testing (FSIGTT) Total Body Insulin Sensitivity Index (SI)

    Time frame: months 3 and 12

  18. FSIGTT Total Body Insulin Sensitivity Index (SI) Disposition Index

    Frequently Sampled Intravenous Glucose Tolerance Testing (FSIGTT) Disposition Index (DI), calculated as the product of the AIRglu and the Total Body Insulin SI

    Time frame: months 3 and 12

  19. Islet Autoantibodies

    Islet Autoantibodies

    Time frame: months 3, 12, 24, and 36

  20. Fecal Elastase

    Fecal Elastase (ug/g)

    Time frame: months 3, 12, 24, and 36

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data from final locked datasets will be made available to other researchers outside the DREAM investigative team. The plan for data sharing incorporates a strategy that recognizes the importance of protecting participants' rights to individual privacy and is compliant with HIPAA regulations and NIH requirements (https://grants.nih.gov/grants/policy/data_sharing/).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will become available one year after publication of the primary manuscript of the DREAM study. The data will be available indefinitely at the NIDDK Central Repository.

Access criteria: Instructions for requesting data from the NIDDK Central Repository appear at the following web site: https://repository.niddk.nih.gov/pages/overall_instructions/

Data sharing details ↗ · repository.niddk.nih.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2030, 96 months after the start.

Of 82 non-industry observational studies under Pancreatitis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 133. This study's planned 96 months is above that.

Counting every sponsor, half of 86 studies reached it within 50 months; a quarter within 21 and three quarters within 133.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2021
First posted
Jan 20, 2022
StartActual
Jan 14, 2022
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: m•••@pennstatehealth.psu.edu · •••1258→b•••@pennstatehealth.psu.edu · •••7178. See the current contact
Nov 19, 2026
Sponsor
Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Sponsor Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
    Contact Study contact changed: m•••@pennstatehealth.psu.edu · •••1258→b•••@pennstatehealth.psu.edu · •••7178. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05197920
Responsible party
Vernon Michael Chinchilli (Distinguished Professor, Milton S. Hershey Medical Center) — Principal investigator
First posted
Jan 20, 2022
Start date
Jan 14, 2022
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Brenda Phillips, DrPH
Contact
bphillips@pennstatehealth.psu.edu
717-531-7178
Kendall T Baab, BS
Contact
kthomas4@pennstatehealth.psu.edu
717-531-6308
Vernon M Chinchilli, PhD
principal investigator · Penn State College of Medicine
Dhiraj Yadav, MD, MPH
study chair · University of Pittsburgh
Melena D Bellin, MD
study chair · University of Minnesota
Phillip A Hart, MD
study chair · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion